gossypol has been researched along with imatinib mesylate in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, X; Fu, J; Li, H; Li, J; Li, Y; Liu, H; Liu, Y; Meng, Y | 1 |
| Bränström, R; Chen, Z; Cui, HL; Gao, J; Huang, WK; Larsson, C; Li, S; Lui, WO; Shi, H; Yeh, CN; Yuan, J | 1 |
3 other study(ies) available for gossypol and imatinib mesylate
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
(-)Gossypol and its combination with imatinib induce apoptosis in human chronic myeloid leukemic cells.
Topics: Apoptosis; bcl-X Protein; Benzamides; Caspase 3; Cell Proliferation; Cytochromes c; Down-Regulation; Drug Evaluation, Preclinical; Enzyme Activation; Fusion Proteins, bcr-abl; Gossypol; Humans; Imatinib Mesylate; K562 Cells; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Membrane Potential, Mitochondrial; Mitochondria; Myeloid Cell Leukemia Sequence 1 Protein; Neoplasm Proteins; Piperazines; Proto-Oncogene Proteins c-bcl-2; Pyrimidines | 2007 |
Heterogeneity of Metabolic Vulnerability in Imatinib -Resistant Gastrointestinal Stromal Tumor.
Topics: Antimycin A; Cell Death; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Energy Metabolism; Gastrointestinal Stromal Tumors; Gene Expression Regulation, Neoplastic; Glycolysis; Gossypol; Humans; Imatinib Mesylate; Oligomycins; Organelle Biogenesis; Oxidative Phosphorylation; Phenotype; Pyruvates | 2020 |